Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Novaferon - Genova Biotech Company

Next Previous
Drug Profile

Novaferon - Genova Biotech Company

Alternative Names: Recombinant anti-tumour and anti-virus protein - Genova Biotech

Latest Information Update: 03 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genova Biotech Company
  • Developer Genova Biotech Company; M. D. Anderson Cancer Center; National Cancer Institute (USA); The Affiliated Hospital of the Chinese Academy of Military Medical Science
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Interferon replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Colorectal cancer
  • Phase II Hepatitis B
  • Phase I/II Liver cancer
  • No development reported COVID 2019 infections; Neuroendocrine tumours; Pancreatic cancer

Most Recent Events

  • 03 Feb 2026 No development reported - Phase-III for COVID-2019 infections (In adults, Adjunctive treatment) in Brazil (Inhalation)
  • 03 Feb 2026 No development reported - Phase-III for COVID-2019 infections in Japan (Inhalation)
  • 28 Oct 2021 Phase-III clinical trials in COVID-2019 infections in Japan (Inhalation) (NCT05172037)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top